^
    1d
    Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2024 --> Jan 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imfinzi (durvalumab) • Calquence (acalabrutinib)
    2d
    BRUIN CLL-322: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (clinicaltrials.gov)
    P3, N=600, Active, not recruiting, Loxo Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs)
    9d
    IGHV (Immunoglobulin Heavy Chain Variable-Region) Gene Mutational Status Validation and Subsequent First-Year Experience (AMP 2024)
    Based on our experience, SHM status can be achieved by routine NGS testing. Our first-year mutated-versus-unmutated test results are reasonably close to what is reported in the literature, supporting the effectiveness of this assay. The majority (66.6%) of QNS samples were due to lack of evidence of clonality in CLL samples.
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    LymphoTrack® Dx IGH Assay
    15d
    Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq® (ASH 2024)
    VO is highly effective and feasible in both academic and community settings. The ability of obi to debulk patients prior to ven initiation allowed most patients to receive ven initiation in the outpatient setting. TLS is rare and was only seen secondary to obi.
    Clinical • Real-world evidence • Real-world
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab)
    17d
    Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation (clinicaltrials.gov)
    P=N/A, N=104, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    Calquence (acalabrutinib)
    17d
    Benefit VA: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, VA Office of Research and Development | Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Jun 2029 --> Jun 2030
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    17d
    Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Jennifer R. Brown, MD, PhD | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial primary completion date
    |
    Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy)
    18d
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclosporin A microemulsion
    23d
    Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    sonrotoclax (BGB-11417)
    23d
    Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study (clinicaltrials.gov)
    P=N/A, N=67, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=50 --> 67
    Enrollment closed • Enrollment change
    |
    Calquence (acalabrutinib)
    24d
    Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy (clinicaltrials.gov)
    P2, N=4, Terminated, M.D. Anderson Cancer Center | N=44 --> 4 | Trial completion date: Jul 2025 --> Oct 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Oct 2024; Slow Accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Arzerra (ofatumumab)
    26d
    Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study. (PubMed, Ann Med)
    Whole-exome sequencing and copy-number analysis revealed that tMZL derives from the divergent evolution of an ancestral common progenitor clone (CPC). Collectively, this study provides clinicopathological characteristics of three common types of transformed lymphomas and the genetic profile of tMZL with diagnostic and therapeutic implications.
    Retrospective data • Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • CREBBP (CREB binding protein) • CARD11 (Caspase Recruitment Domain Family Member 11) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3)
    29d
    Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=106, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    1m
    The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas. (PubMed, Future Oncol)
    Particularly, IGH-BCL2 and IGH-CCND1 fusions were concordant between plasma and tumor biopsies in FLs (91.1%) and MCLs (91.3%), respectively. Longitudinal data demonstrated that ctDNA clearance correlated with complete response but ctDNA increases preceded radiological relapses. ctDNA exhibited high concordance with tumor biopsy in detecting genetic aberrations and demonstrated potential as a promising noninvasive approach to disease surveillance in non-DLBCL NHLs.
    Journal • IO biomarker • Circulating tumor DNA
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1)
    |
    Hemasalus™
    1m
    A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL (clinicaltrials.gov)
    P2, N=27, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | N=50 --> 27
    Trial completion • Enrollment change
    |
    CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Zydelig (idelalisib) • Arzerra (ofatumumab)
    1m
    Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=63, Recruiting, Thomas Jefferson University | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • melphalan • fludarabine IV
    1m
    NCI-2021-03969: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies (clinicaltrials.gov)
    P1, N=25, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    PLCG2 (Phospholipase C Gamma 2)
    |
    cyclophosphamide • bendamustine • fludarabine IV
    1m
    Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Jennifer R. Brown, MD, PhD | Trial primary completion date: Jan 2025 --> Dec 2023
    Trial primary completion date
    |
    Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy)
    1m
    Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax (clinicaltrials.gov)
    P2, N=44, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    1m
    64Cu-LLP2A for Imaging Hematologic Malignancies (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Washington University School of Medicine
    New P1 trial
    1m
    Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Sep 2024 --> Mar 2025
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule)
    |
    lenalidomide • Arzerra (ofatumumab)
    1m
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=225, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2028
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    2ms
    A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=102, Completed, Oncternal Therapeutics, Inc | Active, not recruiting --> Completed
    Trial completion
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Imbruvica (ibrutinib) • zilovertamab (UC-961)
    2ms
    Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=39, Completed, University of Rochester | Active, not recruiting --> Completed
    Trial completion
    |
    Calquence (acalabrutinib) • Rituxan Hycela (rituximab/hyaluronidase)
    2ms
    Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE. (PubMed, Blood)
    Incidence of atrial fibrillation/flutter was lower with zanubrutinib vs ibrutinib (7.1% vs 17.0%); no cardiac deaths were reported with zanubrutinib vs six cardiac deaths with ibrutinib. This analysis, at 42.5 months median follow-up, demonstrates that zanubrutinib remains more efficacious than ibrutinib with an improved overall safety/tolerability profile.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
    2ms
    Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=52, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    2ms
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    2ms
    PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=86, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Sep 2025 --> Sep 2034
    Trial completion date
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    TP53 mutation • CD20 expression • CD19 expression • TP53 expression
    |
    Imbruvica (ibrutinib)
    2ms
    A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Oct 2028 --> Oct 2034
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14) • CD20 expression • CD19 expression
    |
    Imbruvica (ibrutinib) • fludarabine IV
    2ms
    A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=249, Not yet recruiting, Loxo Oncology, Inc.
    New P2 trial
    |
    Jaypirca (pirtobrutinib)
    2ms
    Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Dec 2026 --> Dec 2025
    Trial completion date • IO biomarker
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • NOTCH1 mutation • SF3B1 mutation
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV
    2ms
    CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Joseph Tuscano | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)
    2ms
    CLOVER-WaM: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Cellectar Biosciences, Inc. | Trial completion date: Jun 2025 --> Dec 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    iopofosine I-131 (CLR 131)
    2ms
    1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, University of Maryland, Baltimore | N=34 --> 17
    Enrollment change
    |
    Zydelig (idelalisib)
    2ms
    BGB-A317-3111-10188-101: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov)
    P1/2, N=97, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    paclitaxel • Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib) • BGB-10188
    2ms
    Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Surgery
    |
    CD20 negative
    |
    Keytruda (pembrolizumab)
    2ms
    Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Mayo Clinic | Trial completion date: Feb 2026 --> Oct 2027
    Trial completion date
    |
    Imbruvica (ibrutinib) • Darzalex (daratumumab)
    2ms
    Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
    |
    CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab)
    2ms
    Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=3, Terminated, Academic and Community Cancer Research United | N=63 --> 3 | Trial completion date: Apr 2029 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2027 --> Mar 2024; Trial closed due to low accrual rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    2ms
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions. (PubMed, Br J Haematol)
    This review explores the rationale for discontinuing B-PLL and HCLv diagnoses. It then examines the concept of SBLPN, offers practical guidance for diagnosis and discusses future directions in classifying splenic B-cell lymphomas.
    Review • Journal
    |
    CD5 (CD5 Molecule)
    2ms
    "Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): unraveling the biological gray zone of CLL/SLL in the era of novel therapies. (PubMed, Virchows Arch)
    The overall survival of patients with A-CLL/SLL was significantly lower than C-CLL/SLL (median survival: 6.17 years vs. not reached; 2 and 5-year survival rates: 75.5% vs. 94.7% and 53.3% vs. 93.7%, respectively; p < 0.0001); however, novel agents have improved the outcomes dramatically compared to the previously published data in the pre-BTKi era. Our results support the categorization of A-CLL/SLL as a distinct biologically aggressive subtype of CLL/SLL and highlight the need to revise the diagnostic criteria utilizing a multifaceted approach that integrates the overall pathobiological profile of the disease, in addition to the histology.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    3ms
    A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Aptose Biosciences Inc. | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    luxeptinib (CG-806)